Studies of a transgenic mouse model of Huntington's disease have led to the identification of protein deposits in neuronal nuclei in CAG repeat expansion diseases. The relationship between neuropathology and these nuclear inclusions points to their possible role in pathogenesis.
It was over 125 years ago that George Huntington first described the disease that now bears his name. In the subsequent century, the autosomal dominant hereditary nature of Huntington's disease (HD) and its characteristic neuropathology were described, and the relationship recognised between this profound atrophy of the caudate and lentiform nuclei and the insidious development of choreiform dyskinesias that are such a central feature of the disease process. However, other behavioural and cognitive symptoms are very common in HD, and recently it has been accepted that there is a substantial neuropathology of cortical and other regions outside the basal ganglia which may well underlay the non-motor symptoms of the disease. These psychiatric and personality problems, along with a progressive dementing process, present at least as great a challenge as the movement disorders in the management and care of HD.
The past 25 years have seen enormous advances in our understanding of the disease. Research in the 1970s started to define the neurotransmitter pathology of HD, in which a profound striatal deficit of GABA is found in the absence of substantial deficits in monoamine transmitter systems, in contrast to the monoamine deficits occurring in Parkinson's and Alzheimer's diseases. Unfortunately, and again in contrast to those other neurodegenerative disorders, these advances have not led to substantial improvements in drug treatment. Nevertheless, animal models have been developed in which certain neurotoxins mimic (albeit acutely) the specificity of the striatal neuronal damage of HD, thereby providing clues as to possible toxic mechanisms of neurodegeneration. Useful recent models reminiscent of HD involve mitochondrial toxins such as 3-nitropropionic acid; 1 some support for the validity of this approach is provided by the observation of reduced activity of complex II in striatal tissue from HD patients. 2 But the most exciting recent development has been the identification of the HD gene. This reflected a decade-long search following its localisation to the short arm of chromosome 4, 3 culminating in the identifiCorrespondence: GP Reynolds, Dept of Biomedical Science, University of Sheffield, Sheffield S10 2TN, UK cation of a gene containing a CAG trinucleotide repeat sequence that was expanded to beyond 35 repeats in cases of HD. 4 As well as providing a means for unequivocal pre-symptomatic diagnosis, this finding introduced a new era of enormous advances in our understanding of the disease. Thus the age-of-onset of disease symptoms is closely related to the number of CAG repeats; as the repeat length expands, the disease manifests earlier. 5 This observation elucidated the phenomenon of anticipation, in which illness onset often occurs earlier in the second generation when transmission of the HD gene is from the father. Anticipation is due to a tendency to increased repeat number in the affected offspring of HD fathers and reflects the repeat-length instability that is associated with spermatogenesis. 5 HD is one of several trinucleotide repeat diseases including the various spinocerebellar atrophies (SCA1-3, 6 and 7), dentatorubralpallidoluysian atrophy and spinobulbar muscular atrophy. This group of disorders (type I) are associated with translated CAG repeat expansions coding for polyglutamine; in most of these disorders the pathological repeat number is similar to that found in HD. Type II disorders include fragile X syndrome and Friedrich's ataxia, and are associated with abnormal expansions of other trinucleotide sequences of over 200 repeats. Of the type I disorders, only those protein products of the genes involved in spinobulbar muscular atrophy and SCA6 have known normal function, being associated with the androgen receptor and a calcium channel subunit respectively.
The normal HD gene is expressed widely, with both mRNA and protein product being found in many human tissues; highest levels of the protein product are reported in the brain.* Within this tissue the regional distribution appears to be fairly unselective, although somewhat higher levels are found in some regions, including cerebellum and cerebral cortex, than *The term 'huntingtin' is used in the literature to describe the product of the HD gene. However some confusion may arise in that huntingtin-immunoreactivity does not always distinguish between the partial transgene product, the truncated product observed in the NII and the native full-length protein product, and thus we have avoided the use of this term here.
others. 6, 7 At the cellular level, HD gene protein product is most concentrated in neurons, within which it is found in the cytoplasm but not nuclei, and appears to be associated with vesicles and nerve terminals. 8, 9 Interestingly, the expression of the expanded gene in HD is apparently no different from that of the normal gene, with no correlation to brain regions involved in the disease pathology. 7, 8 Thus the normal function of the gene remains elusive, although its inactivation in mice results in non-viable homozygote embryos that undergo early death, while heterozygotes for the inactive gene are phenotypically normal. 10 This underlines the gain of function that the abnormal gene must be imposing on the organism in HD, an effect that is presumably not directly related to the putative role of the gene product in normal embryonic development.
Despite the advances in defining the gene responsible for HD, we still know almost nothing of the mechanism whereby the abnormal gene containing an expanded CAG repeat brings about the characteristic pattern of neuropathology in the disease. There have been several proposals based on the observation that the increased length of polyglutamine may bind functional proteins and thereby interfere with normal cellular function. Proteins that have been implicated in this mechanism of pathogenesis include glyceraldehyde-6-phosphate dehydrogenase (GAPDH), 11 calmodulin 12 and two novel proteins. 13, 14 Given the importance of mitochondrial toxicity in the development of animal models of HD, one possible neurotoxic mechanism is that such an interaction of the HD gene product may interfere with mitochondrial energy metabolism. How- ever, these hypotheses do not easily explain the regional selectivity of HD pathology, nor are they always consistent with other biochemical determinations; there is no apparent decrease of GAPDH activity in the HD brain, for example. 2 Another problem that has yet to be overcome is the fact that the various type I trinucleotide repeat disorders, all of which are associated with similar increases in polyglutamine sequences in expressed proteins, affect different neuronal systems.
Nevertheless, some recent intriguing findings have shed light on the possible mechanisms of neuronal degeneration in type I trinucleoide repeat disorders. These findings have emerged following the development of a transgenic animal model of HD. This has not been easy; initial attempts to generate a mouse line expressing the human HD gene containing an extended repeat sequence were confounded by problems associated with the large size (approx 210 kb) of the human HD gene and the instability of highly expanded CAG repeat sequences. However, with a fragment of the gene containing the promoter region, exon 1 (which contains the CAG repeat sequence) and a part of intron 1, it has proven possible to generate transgenic mice that, in the most studied line, carry expansions of 141-157 CAG repeats. Most importantly, these animals have a progessive, complex neurological phenotype from 2 months, deteriorating rapidly over the following month. The mice exhibit a motor disorder including a resting tremor, abrupt shuddering movements, stereotypic grooming and seizures (Table 1) . 15 Initial histological studies failed to identify a patho-logical basis for the behavioural phenotype of these mice. Although the size of the brain is reduced by 20%, this effect appears not to be selective for any particular brain structure(s); in particular, no relative atrophy of the striatum is apparent, in strong contrast to the findings in HD. 15 Consistent with this, our investigation of the neurotransmitter abnormalities of the transgenic mice showed no GABAergic deficit, although there are intriguing deficits in monoamine neurotransmitters (Reynolds et al, in preparation) . Similarly, the loss of striatal glutamate/NMDA receptors seen in HD is not found in these mice (Cha et al, submitted for publication). Nevertheless, this animal model has importantly provided the first of several strong indications pointing to the possible mechanisms of neuronal death in HD and other type I trinucleotide repeat diseases.
Using antibodies generated against the N-terminal portion of the protein product, Davies et al 16 have shown that the transgenic mice described above show staining of abnormal neuronal intranuclear inclusions (NII). These NII are large deposits (usually bigger in diameter than the nucleolus) of the transgene protein product which are found frequently in neuronal nuclei of the cerebral cortex, cerebellum and striatum, but are much less dense in the hippocampus, thalamus and globus pallidus. NII also stain for ubiquitin, indicating that the deposits of transgene protein have been tagged for proteolysis and are, by corollary with the amyloid deposits and the Pick and Lewy bodies found in other late-onset neurodegenerative diseases, accumulations of unwanted but intractable protein.
This report was rapidly followed by the observation in postmortem HD brain of similar NII immunoreactive for both the N-terminal protein product and ubiquitin. 17 The regional distribution of NII staining is somewhat more limited in HD, with positive findings in the cortex and striatum, but no deposits seen in the globus pallidus or cerebellum. This is surprising considering the substantial neuronal loss that occurs in the globus pallidus 18 and the increasing recognition of Purkinje cell deficits in HD, 19 indicating a substantial lack of correlation between the appearance of NII and the pattern of neuronal loss and tissue atrophy in the disease.
Nevertheless, the NII could compromise neuronal viability by interfering with normal nuclear function, thus providing a tempting hypothesis to link these findings to the pathogenesis of HD. Providing support for the importance of internuclear deposits in the neurodegenerative process are the similar findings recently reported in two other type I trinucleotide repeat diseases SCA3 20 and SCA1. 21 These disorders show a distribution of NII that, in contrast to HD, closely parallels the brain regions particularly targeted by the disease. In addition, mice containing the human SCA1 transgene, and cell lines transfected with this gene, have provided some clues as to the mechanism whereby these neuronal deposits in CAG repeat diseases might induce neuronal dysfunction and death. Skinner et al 21 have shown that the SCA1 gene product ataxin-1 is a nuclear matrix-associated protein, but when it contains the expanded polyglutamine sequence it forms NII and results in a disruption of the nuclear matrix.
Mutant ataxin-1 and ataxin-3 (the SCA3 gene product) both appear to be deposited as complete proteins in the NII. The same is not true in HD; immunocytochemistry using antibodies raised against the N-terminal of the HD gene product (close to the repeat sequence), and against a sequence at an internal site at amino acids 585-725, have shown the former, but not the latter part of the gene product is deposited in the HD NII. 17 Thus some proteolysis of the gene product occurs prior to its deposition. One suggested mechanism involves apopain, which is found to cleave the gene product to form a 50-60 kDa protein; 22 this process is apparently modulated by the length of polyglutamine such that longer sequences result in more rapid breakdown. Of course, the transgenic HD mouse only contains a relatively small fragment of the HD gene and would not necessarily undergo further proteolysis prior to deposition.
What is responsible for the regional selectivity of the type I trinucleotide repeat diseases? The answer to this important question remains elusive, although work with the SCA1 models has provided an important clue. It is shown that the ataxin-1 binds to a protein, leucinerich acidic nuclear protein (LANP) that is expressed predominantly in the neurons that are particularly affected in SCA1, the Purkinje cells. 23 This interaction is stronger as the polyglutamine sequence of ataxin-1 increases, and it is conceivable that the interaction between LANP and ataxin-1 results in NII formation and eventually neuronal pathology in SCA1. By analogy with these findings, it could be valuable to identify possible interactions between the expanded HD gene product and proteins specific to nuclei of neurons degenerating in HD, for example, GABAergic striatal neurons.
But is there an analogous mechanism of cell death in HD? As mentioned above, the lack of correlation with regional pathology argues against a clear-cut relationship between NII deposition and neuronal death in HD. Interestingly, profound differences are seen in the extent of NII staining between juvenile and adult cases of HD, where the former exhibited up to 52% NII occurrence in cortical neurons, while only 3-6% of these neurons were affected in adult HD. 17 This orderof-magnitude difference is a poor correlate of the histopathological differences between adult and juvenile HD which tend to be more subtle. Juvenile HD has a symptom profile with features such as rigidity, epilepsy and cerebellar signs that in the adult are rare and/or are found in later stages of the disease. These symptoms reflect a more rapid time course and a less circumscribed neuropathology in which cortical and Purkinje cells are severely diminished, along with a more generalised pathology of the basal ganglia. However, this still does not resemble the transgenic mouse model. The pattern of neurotransmitter loss in juvenile HD is, at post mortem, no different from adult cases (GP Reynolds and SJ Pearson, unpublished) and cer-tainly does not show the profound dopamine deficits we find in the HD mouse.
There is another pathological feature that is, however, found in HD brain but not reported in the animal model. Dystrophic neurites, containing deposits of the N-terminal protein product similar to the NII, 17 have previously been identified in the cortex using ubiquitin antibodies. 24 These dystrophic neurites appear to be a common feature of adult onset cases but are much sparser in the cortex of juvenile cases. 17 Although not fully studied, they are observed in the striatum, although again there appears no clear correlate with the regional selectivity of pathology.
While it seems likely that NII formation is responsible for the neurological dysfunction in the transgenic HD mice, the differences in pathology, symptoms and NII distribution make it hard to conclude that the same mechanism occurs in adult HD. It may be that NIImediated neurodegeneration contributes to the juvenile disease, although the pathology remains more circumscribed than in the transgenic model. Some other pathological process is likely to underlie the specificity of neuronal loss in HD, although the difficulties in determining correlates of pathology from end-stage autopsy tissue samples with substantial neuronal loss are clear. Inevitably we shall continue to look to genetic models employing other, less severely affected, lines from Bates' invaluable series of transgenic mice, 15 as well as other mouse models, such as that in which the CAG sequence of the endogenous HD gene is expanded. 25 It is important not to forget the valuable clues provided by neurotoxic models, particularly those implicating disruption of energy metabolism; the study of such disrupted metabolic process can be undertaken in vitro in cultured neurons containing transfected gene or gene fragments. With these improved models, and an understanding of the pathogenic process, we should be in a position to develop preventative drug therapy for what is a profoundly distressing, and poorly treated, neurodegenerative disease.
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